Asset Details
Do you wish to reserve the book?
Nuclear localization of Y-box factor YB1 requires wild-type p53
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nuclear localization of Y-box factor YB1 requires wild-type p53
Do you wish to request the book?
Nuclear localization of Y-box factor YB1 requires wild-type p53
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nuclear localization of Y-box factor YB1 requires wild-type p53
2003
Overview
Nuclear localization and high levels of the Y-box binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we explore a role for p53 in the nuclear localization of YB1. We report that various genotoxic stresses induce nuclear localization of YB1 in a small proportion of treated cells, but only in cells with wild-type p53. We go on to show directly that functional p53 is required for YB1 to translocate to the nucleus. Tumor-associated p53 mutants however are attenuated for YB1 nuclear localization as are mutants mutated in the proline-rich domain of p53. These data link the DNA-damage response of p53 to YB1 nuclear translocation. In addition, we find that YB1 inhibits p53-induced cell death and its ability to trans-activate promoters of genes involved in cell death signaling. Together these data suggest that some forms of p53 cause YB1 to accumulate in the nucleus, which in turn inhibits p53 activity. These results provide a possible explanation for the correlation of nuclear YB1 with drug resistance and poor prognosis in some tumor types, and for the first time implicate p53 in the process of nuclear translocation.
Publisher
Nature Publishing Group UK,Nature Publishing,Nature Publishing Group
Subject
Active Transport, Cell Nucleus
/ Antineoplastic Agents - pharmacology
/ Biological and medical sciences
/ CCAAT-Enhancer-Binding Proteins - genetics
/ CCAAT-Enhancer-Binding Proteins - metabolism
/ Fundamental and applied biological sciences. Psychology
/ Genes
/ Humans
/ Kinetics
/ Medicine
/ Molecular and cellular biology
/ Mutants
/ Oncology
/ Plasmids
/ Proline
/ Proteins
/ Recombinant Fusion Proteins - metabolism
/ Transcription Factors - genetics
/ Transcription Factors - metabolism
/ Tumor Suppressor Protein p53 - genetics
/ Tumor Suppressor Protein p53 - metabolism
/ Tumors
